Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News

Merck’s Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer

By Vandana Singh
November 1, 1:51 PM
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda, in combination with gemcitabine and cisplatin, for locally advanced unresectable or 

MRK

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Healthcare Analytics Solutions Provider IQVIA Cuts Annual Forecast, Sees Demand Slowing For Services

By Vandana Singh
November 1, 1:47 PM
IQVIA Holdings Inc (NYSE: IQV) reported Q3 sales of $3.74 billion, up 4.9% Y/Y on a reported basis and 4.1% at constant currency (CC), 

IQV

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • M&A
  • News
  • Rumors

Potential Takeover In Works for Cardiovascular Treatment Focused Cytokinetics

By Vandana Singh
November 1, 1:38 PM
Cytokinetics Inc (NASDAQ: CYTK), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover options as it has garnered interest from at least one major pharmaceutical company in recent months.

CYTK

Read More
2 minute read
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss

By Vandana Singh
November 1, 1:31 PM
Bayer AG (OTC: BAYRY) (OTC: 

BAYRY

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

Why Is Cancer Focused Monopar Therapeutics Stock Trading Higher Today?

By Vandana Singh
November 1, 1:22 PM
Monopar Therapeutics Inc (NASDAQ: MNPR) will present data from its ongoing Phase 1b open-label, dose-escalating trial of camsirubicin in patients with advanced soft tissue sarcoma later today at the 2023 Connective Tissue Oncology Society 

MNPR

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Penny Stocks

Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?

By Vandana Singh
November 1, 1:20 PM
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company 

AZN

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Is There An Opportunity To Buy IDEXX Labs, The Animal Diagnostics-Focused Firm Stock After Q3 Performance? Analyst Answers

By Vandana Singh
November 1, 12:32 PM
IDEXX Laboratories Inc (NASDAQ: IDXX) reported Q3 FY23 sales of $915.53 million, missing the consensus of $926.76 million

IDXX

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Insurance Firm Humana Shares Fall After Q3 Performance – Here’s Why

By Vandana Singh
November 1, 12:23 PM
Humana Inc (NYSE: HUM) reported Q3 adjusted EPS of $7.78 compared to $7.31 a year ago, beating the consensus of $7.16.

HUM

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Trading Ideas

CVS Health’s Health Services And Pharmacy Benefit Management Business Show Strength In Q3, But Lowers Annual GAAP EPS Outlook

By Vandana Singh
November 1, 9:02 AM
CVS Health Corp's (NYSE: CVS) Q3 sales increased 10.6% Y/Y to $89.76 billion, beating the consen

CVS

Read More
1 minute read
  • Buybacks
  • Exclusives
  • General
  • Health Care
  • Market-Moving Exclusives
  • News
  • Small Cap
  • Top Stories

EXCLUSIVE: Medical Devices Firm Zynex Launches New $20M Share Repurchase Program

By Vandana Singh
November 1, 8:30 AM
Zynex Inc's (NASDAQ: ZYXI) board of directors approved a program to repurchase up to $20.0 million.  The program will commence on November 1, 2023, and is scheduled to terminate earlier than November 1, 2024, or when the $20.0 million limit is reached. 

ZYXI

Posts pagination

Previous 1 … 129 130 131 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service